{"id":"NCT04896008","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","briefTitle":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-01","primaryCompletion":"2024-07-26","completion":"2025-02-18","firstPosted":"2021-05-21","resultsPosted":"2025-08-22","lastUpdate":"2025-08-22"},"enrollment":173,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Sotatercept","otherNames":["MK-7962","ACE-011"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Sotatercept","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension \\[PAH\\] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of â‰¥24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.","primaryOutcome":{"measure":"Time to First Confirmed Morbidity or Mortality Event","timeFrame":"Up to approximately 26 months","effectByArm":[{"arm":"Sotatercept","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":9.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":21},"locations":{"siteCount":57,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Mexico","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["40167274"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":86},"commonTop":["Epistaxis","Headache","Diarrhoea","Nausea","Oedema peripheral"]}}